Is Regeneron Stock A Buy Right Now?

REGNYTD+24.3%SPYYTD+11.5%XLVYTD+23.5%
Analyze REGN →

For questions about this article or underlying research, email help@trefis.com.

Regeneron Pharmaceuticals (REGN) stock returned 40.9% over the past twelve months, against 11.7% for the S&P 500. For a buyer today, the answer depends on whether Regeneron’s bigger cut of Dupixent profits from Sanofi can keep outgrowing the falling sales of its older eye drug, EYLEA. Regeneron’s operating profit has grown fast, but so has its share price. So what does a buyer pay for Regeneron’s earnings after that run?

Image from Pixabay

On Earnings, Regeneron Costs Less Than The S&P 500

Even after that run, Regeneron trades at 20.2 times its earnings over the twelve months to September 30, 2026, against 21.9 for the S&P 500. At that valuation, a buyer gets a business far more profitable than the broader index. Regeneron’s operating margin over those twelve months was 30.4%, against 18.9% for the S&P 500.

The quarterly operating margin has also widened, reaching 40.5% in fiscal Q3 2026, up from 29.6% in fiscal Q3 2025.

Where Is Regeneron’s Revenue Jump Coming From?

The jump comes mostly from Sanofi, Regeneron’s partner on Dupixent. Regeneron’s revenue rose 36.3% from a year earlier to $5.12 billion in fiscal Q3 2026, an increase management said came primarily from higher Sanofi collaboration revenue.

Regeneron’s share of the profits from that alliance rose 77%. Management tied that rise to growing Dupixent sales and to Regeneron finishing the repayment of a development balance owed to Sanofi in the second quarter. That milestone made the third quarter the first period in which Regeneron recorded its full share. Meanwhile, Dupixent’s U.S. sales grew 40% to $5 billion in the quarter.

That repayment can only be finished once. Any further gains in Regeneron’s share would have to come mostly from Dupixent selling more.

Regeneron’s Older Eye Drug Is Shrinking Fast

U.S. sales of EYLEA fell 41% from a year earlier to $400 million in fiscal Q3 2026. Management expects demand for the drug to fall again in the fourth quarter by a low- to mid-teens percentage from the third, while also describing increasing competition from additional biosimilar launches.

The newer EYLEA HD is taking the older drug’s place, with U.S. sales up 62% to $699 million. Yet combined U.S. sales of the two drugs were $1.1 billion, down 1% from a year earlier. Regeneron’s U.S. eye business is not adding growth, though management says the franchise remains in a strong position.

Regeneron Expects A One-Time Payment In Fiscal Q4 2026

Under its expanded alliance with Sanofi, Regeneron expects to record a $1 billion upfront payment as collaboration revenue in the fourth quarter. Third-quarter revenue also included an Ilaris royalty catch-up of approximately $60 million, which management said will not recur in the fourth quarter.

Regeneron is expected to report its fourth quarter in January 2027. Its share of Sanofi collaboration profits, which was $2.6 billion in the third quarter, is the figure to watch.

Does This Mean You Should Act On REGN?

Betting on a single stock is always risky, whichever way you lean. The Trefis High Quality (HQ) Portfolio holds 30 quality companies in equal weight and has returned 105% since its September 2020 launch.

See The HQ Portfolio

Spot an error or want more like this? Tell us in 10 seconds.